This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Metabolic disease				
Metabolic disorders	Peroxisome proliferation-activated receptor- δ (PPARD; PPAR δ)	<p><i>In vitro</i> and mouse studies identified thiazole- and oxazole-based PPARD agonists that could help treat metabolic disorders. In mice, the agonists increased expression of PPARD-regulated genes involved in fatty acid catabolism and energy homeostasis compared with vehicle. Next steps could include evaluating the selective PPARD agonists in animal models of metabolic disorders.</p> <p>MBX-8025, a PPARD agonist from Metabolex Inc., is in Phase II testing to treat dyslipidemia.</p> <p>SAR351034, a PPARD agonist from sanofi-aventis Group, is in Phase I testing to treat dyslipidemia and diabetes.</p> <p>SciBX 3(2); doi:10.1038/scibx.2010.60 Published online Jan. 14, 2010</p>	Patent and licensing status unavailable	<p>Epplé, R. <i>et al. J. Med. Chem.</i>; published online Nov. 20, 2009; doi:10.1021/jm9007399</p> <p>Contact: Robert Epplé, The Genomics Institute of the Novartis Research Foundation, San Diego, Calif. e-mail: repple@gnf.org</p>